#AANAM – Nipocalimab Safely Eases gMG Symptoms, Final Trial Data Confirm

#AANAM – Nipocalimab Safely Eases gMG Symptoms, Final Trial Data Confirm

293003

#AANAM – Nipocalimab Safely Eases gMG Symptoms, Final Trial Data Confirm

Editor’s note: The Myasthenia Gravis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Janssen’s experimental therapy nipocalimab (M281) safely, rapidly, and effectively reduced disease severity in adults with generalized myasthenia gravis (gMG), according to final data from the Phase 2 Vivacity-MG trial. “The utility of currently available [MG] medicines is limited, and many patients fail to adequately…

You must be logged in to read/download the full post.